Search CommunityWalk:


Micromet Inc

9201 Corporate Boulevard, Suite 400
Suite 505
Rockville, MD 20850, USA

Category: Biotechnology/Biopharmaceutical

Used in the following map:

Maryland Biotech Industry Map

Micromet Inc is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. It was founded in 1993, with a goal to discover, develop and commercialize breakthrough therapies with the potential to deliver meaningful clinical benefit to oncology patients. Its vision is to develop a new class of drugs that mobilize T cells, the body's most potent killer cells, enabling them to detect and destroy normally unrecognizable cancer cells.

Micromet advances a robust pipeline of therapeutics based on its proprietary BiTE® technology. Its product candidate blinatumomab (MT103) has demonstrated single-agent activity in both adult and pediatric patients with acute lymphoblastic leukemia. The company's products include: Blinatumomab (MT103), a Bispecific T cell Engager (BiTE®) antibody designed to direct a patient's T cells, the body's most potent killer cells, against cancer cells that express CD19; MT110 and MT111 (also known as MEDI-565), a Bispecific T cell Engager (BiTE)® antibody for the treatment of solid tumors; MT203 for the treatment of acute and chronic inflammatory and autoimmune diseases including rheumatoid arthritis, asthma and multiple sclerosis; and MT228 for the treatment of metastatic melanoma.

Micromet has partnerships with Boehringer Ingelheim GmbH, Lonza Group Ltd, Sanofi-aventis, Bayer Ag, Bayer Schering Pharma AG, Nycomed SICAR S.C.A., Affitech A/S, etc.